BEIJING – After being a health care investor for 21 years, Jonathan Wang decided to co-found biotech startup Inmagene Biopharmaceuticals Co. Ltd. in July 2019 to seek success in the China market using the experience and insights he had accumulated over the years.

BEIJING – After being a health care investor for 21 years, Jonathan Wang decided to co-found biotech startup Inmagene Biopharmaceuticals Co. Ltd. in July 2019 to seek success in the China market using the experience and insights he had accumulated over the years. With $20 million in its war chest so far, the startup aims to excel in immunology-related therapeutic areas in China.

Fountain Therapeutics Inc., a California company working to create treatments for age-related diseases, said Khosla Ventures has led a $6 million series A-1 financing of the startup, with participation from Nan Fung Life Sciences, which earlier contributed $5 million to the round.

LONDON – After announcing its $17.4 million series A funding in the midst of pandemic in April, Genespire Srl has now gone public on the preclinical research upon which its programs will be based, presenting the data at last week’s American Society of Gene and Cell Therapy (ASGCT) annual meeting.

CEO and co-founder Rosana Kapeller told BioWorld that Rome Therapeutics Inc.’s $50 million series A will fund early work in an “exploding” new area of biology: the repeatome – “the dark genome” or “junk DNA,” as many previously deemed the roughly 60% of the human genome that consists of repetitive sequences of nucleic acids.

HONG KONG – Whether bats are the source of COVID-19 is a debatable point; however, using sound to navigate like them could prove key for diagnostics and disease monitoring. Bat-Call Ltd. is using its auscultation technology in the battle against the pandemic. It said its patented artificial intelligence (AI) infra-sound analysis and deep learning classification technologies can support the early detection and monitoring of COVID-19 patients.

I2O Therapeutics Inc., of Allston, Mass., raised $4 million in seed funding to further its work on oral formulations of therapies typically limited to injections, such as biologics, large molecules and peptide-based pharmaceuticals.

LONDON – Amphista Ltd. becomes the latest to join the growing band of proteolysis targeting chimera (Protac) specialists, arriving on the scene with a $7.5 million series A and what it says is a new approach to targeted protein degradation (TPD).

LONDON – A founding father of anti-angiogenesis therapy, Peter Carmeliet is turning his previous work on its head in new research which indicates that rather than destroying tumor vasculature, it should be piggy-backed as a means to recruit immune cells to a tumor.

TORONTO – That old military saw “an army marches on its stomach” might just as easily apply to transport of much needed ventilators for patients suffering from the coronavirus. Mounting systems for ground and air ambulances like the Bracket Pro Serie for Ventilators launched March 5 by Quebec City-based Technimount System Inc. are the “soldiers” carrying ventilators and other medical devices for hospital bound patients, Technimount CEO Carl Bouchard told BioWorld.